These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 23979202)

  • 1. Association between baseline VEGF/sVEGFR-2 and VEGF/TSP-1 ratios and response to metronomic chemotherapy using cyclophosphamide and celecoxib in patients with advanced breast cancer.
    Perroud HA; Rico MJ; Alasino CM; Pezzotto SM; Rozados VR; Scharovsky OG
    Indian J Cancer; 2013; 50(2):115-21. PubMed ID: 23979202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response.
    Perroud HA; Alasino CM; Rico MJ; Mainetti LE; Queralt F; Pezzotto SM; Rozados VR; Scharovsky OG
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):365-74. PubMed ID: 26721701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response.
    Wong NS; Buckman RA; Clemons M; Verma S; Dent S; Trudeau ME; Roche K; Ebos J; Kerbel R; Deboer GE; Sutherland DJ; Emmenegger U; Slingerland J; Gardner S; Pritchard KI
    J Clin Oncol; 2010 Feb; 28(5):723-30. PubMed ID: 20026801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer.
    Fontana A; Galli L; Fioravanti A; Orlandi P; Galli C; Landi L; Bursi S; Allegrini G; Fontana E; Di Marsico R; Antonuzzo A; D'Arcangelo M; Danesi R; Del Tacca M; Falcone A; Bocci G
    Clin Cancer Res; 2009 Aug; 15(15):4954-62. PubMed ID: 19622584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical usefulness of assessing VEGF and soluble receptors sVEGFR-1 and sVEGFR-2 in women with breast cancer.
    Thielemann A; Baszczuk A; Kopczyński Z; Kopczyński P; Grodecka-Gazdecka S
    Ann Agric Environ Med; 2013; 20(2):293-7. PubMed ID: 23772579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients.
    Perroud HA; Rico MJ; Alasino CM; Queralt F; Mainetti LE; Pezzotto SM; Rozados VR; Scharovsky OG
    Future Oncol; 2013 Mar; 9(3):451-62. PubMed ID: 23469980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer.
    Banerjee S; Pancholi S; A'hern R; Ghazoui Z; Smith IE; Dowsett M; Martin LA
    Clin Cancer Res; 2008 May; 14(9):2656-63. PubMed ID: 18451229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
    Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
    J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The usefulness of determining the serum concentrations of vascular endothelial growth factor (VEGF) and its soluble receptor type 2 (sVEGF-2) in the differential diagnosis of adrenal incidentalomas.
    Foltyn W; Strzelczyk J; Marek B; Kajdaniuk D; Siemińska L; Rosiek V; Kos-Kudła B
    Endokrynol Pol; 2012; 63(1):22-8. PubMed ID: 22378094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers.
    Allegrini G; Di Desidero T; Barletta MT; Fioravanti A; Orlandi P; Canu B; Chericoni S; Loupakis F; Di Paolo A; Masi G; Fontana A; Lucchesi S; Arrighi G; Giusiani M; Ciarlo A; Brandi G; Danesi R; Kerbel RS; Falcone A; Bocci G
    Angiogenesis; 2012 Jun; 15(2):275-86. PubMed ID: 22382585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins.
    Deprimo SE; Bello CL; Smeraglia J; Baum CM; Spinella D; Rini BI; Michaelson MD; Motzer RJ
    J Transl Med; 2007 Jul; 5():32. PubMed ID: 17605814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined VEGF-A and VEGFR-2 concentrations in plasma: diagnostic and prognostic implications in patients with advanced NSCLC.
    Jantus-Lewintre E; Sanmartín E; Sirera R; Blasco A; Sanchez JJ; Tarón M; Rosell R; Camps C
    Lung Cancer; 2011 Nov; 74(2):326-31. PubMed ID: 21481963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.
    Buckstein R; Kerbel RS; Shaked Y; Nayar R; Foden C; Turner R; Lee CR; Taylor D; Zhang L; Man S; Baruchel S; Stempak D; Bertolini F; Crump M
    Clin Cancer Res; 2006 Sep; 12(17):5190-8. PubMed ID: 16951238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Assessment of pro- and antiangiogenic factors blood serum concentrations in patients with hormonal inactive adrenal tumors].
    Korzeniewska M; Kołomecki K; Stepień H; Naze M; Stepień T; Kuzdak K
    Endokrynol Pol; 2005; 56(1):39-44. PubMed ID: 16335673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumoral and antimetastatic effects of metronomic chemotherapy with cyclophosphamide combined with celecoxib on murine mammary adenocarcinomas.
    Mainetti LE; Rozados VR; Rossa A; Bonfil RD; Scharovsky OG
    J Cancer Res Clin Oncol; 2011 Jan; 137(1):151-63. PubMed ID: 20349084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating biomarkers of bevacizumab activity in patients with breast cancer.
    Denduluri N; Yang SX; Berman AW; Nguyen D; Liewehr DJ; Steinberg SM; Swain SM
    Cancer Biol Ther; 2008 Jan; 7(1):15-20. PubMed ID: 18059178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia.
    Wierzbowska A; Robak T; Wrzesień-Kuś A; Krawczyńska A; Lech-Marańda E; Urbańska-Ryś H
    Eur Cytokine Netw; 2003; 14(3):149-53. PubMed ID: 14656688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced serum vascular endothelial growth factor receptor-2 (sVEGFR-2) and sVEGFR-1 levels in gastric cancer patients.
    Kikuchi S; Obata Y; Yagyu K; Lin Y; Nakajima T; Kobayashi O; Kikuichi M; Ushijima R; Kurosawa M; Ueda J
    Cancer Sci; 2011 Apr; 102(4):866-9. PubMed ID: 21219538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metronomic chemotherapy in metastatic breast cancer: impact on VEGF.
    El-Arab LR; Swellam M; El Mahdy MM
    J Egypt Natl Canc Inst; 2012 Mar; 24(1):15-22. PubMed ID: 23587228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus.
    Robak E; Sysa-Jedrzejewska A; Robak T
    Mediators Inflamm; 2003 Oct; 12(5):293-8. PubMed ID: 14760936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.